Marksans Pharma Q1 FY27 earnings call

Marksans Pharma reported a robust Q1 FY27, with revenue growing 35.6% year-on-year to INR841 crores. This was accompanied by a 112.8% surge in EBITDA to INR213 crores, resulting in an EBITDA margin of 25.3%. Net profit after tax also saw a significant increase of 173.9% to INR159 crores, with a PAT margin of 18.4%. The exceptional performance was largely fueled by the UK and Europe segment, which recorded its highest-ever quarterly revenue of INR356 crores, growing 74.7% year-on-year.

The company's European growth strategy gained momentum with the completion of the acquisition of QliniQ B.V in Netherlands, which contributed INR44 crores to Q1 revenue. The acquisition of ABCnow GmbH in Germany is set to commence consolidation from Q2 FY27. Marksans has also established Marksans Pharma Europe in Ireland and Marksans Pharma GmbH in Germany, signaling a focused effort to build a direct front-end presence across key regulated European markets. Management expects QliniQ to contribute INR150-175 crores for the full year and aims for Europe to reach INR1,000 crores in the next 3-5 years.

North America, the largest market, delivered INR377 crores in revenue, growing 15.1% year-on-year, accounting for 45% of consolidated revenue. While demand was softer during the summer months, the underlying business remains healthy. Australia and New Zealand also showed strong growth, with revenue up 53.7% year-on-year to INR88 crores, in line with seasonal patterns. The company expects momentum to build in these regions throughout the year, contributing to overall growth.

Gross profit increased by 38.9% year-on-year to INR497.3 crores, with gross margin expanding to 59.1%. This improvement was attributed to a favorable product mix, lower cost materials from inventory, and favorable foreign exchange. Management indicated that sustainable gross margins are expected to be around 55-56% as the benefit from existing low-cost inventory normalizes. The company's cash balance crossed INR1,000 crores for the first time, reaching INR1,058 crores, with net cash at INR1,031 crores, despite the payment for the QliniQ acquisition.

Marksans remains disciplined in capital allocation, focusing on inorganic opportunities to drive growth. The company is actively exploring further acquisitions in Europe and aims to double its overall revenue within the next five years. R&D spend for the quarter was INR23.2 crores, or 2.8% of consolidated revenue, reflecting increased investment in product development and differentiated dosage forms. The company is also evaluating the need for additional manufacturing capacity in India, with plans to work towards this objective over the next one to two years.

Management reiterated its FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin, acknowledging geopolitical uncertainties and their potential impact on costs and market conditions. While the US business remains strong, potential trade policy changes (like increased duties) are being monitored, with a wait-and-watch approach. The company also noted the unpredictable nature of US FDA inspections, though one plant was audited less than 12 months prior, highlighting ongoing regulatory oversight.